Navigation Links
New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel
Date:11/6/2009

SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

"Of all the diseases rheumatologists treat, lupus still has the highest unmet need," according to MedPredict president Jeffrey Berk. "While many more people have RA than have lupus, lupus kills, and RA doesn't. There are a plethora of good therapies for RA, but few for lupus. This expert panel weighs in on the leading B-cell inhibitors that are in development for lupus, and provides insight into how different lupus trial designs have thus far driven clinical outcomes."

To develop this analysis, entitled "Thought Leader Insight & Analysis: Rheumatology," MedPredict conducted primary interviews with U.S.-based rheumatology thought leaders around the time of the recent American College of Rheumatology 2009 conference.

Some of the issues analyzed in this report:

  • Reactions to pivotal Phase III data supporting GlaxoSmithKline's Benlysta (belimumab) in systemic lupus erythemetosis (SLE).
  • Impact of the FDA's complete response letter rejecting Genentech's application for Rituxan (rituximab) in RA patients who have previously failed DMARD therapy - do thought leaders think PML safety concerns apply to all B-cell inhibitors?
  • Insight into rheumatologists' decision-making process for selecting treatment for RA. How will anti-TNF newcomers fit into the rheumatologist's armamentarium?
  • Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk, TNF/PDE4, BTK, MEK, and S1P.

Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen/Pfizer, Arana, Array, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Centocor/Schering-Plough, Cytopia, Genentech/Roche, Genentech/Roche/Chugai, GlaxoSmithKline/Genmab, GSK/Human Genome Sciences, Incyte, Lexicon, Lilly, Merck, Merck Serono/ZymoGenetics, Novartis, Pharmacyclics, Rigel, UCB, UCB/Immunomedics, Pfizer/Trubion.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Radiation Therapy Options in Mesothelioma by Veronica Garza of MD Anderson Sponsored by MesoCare.org
2. Clinical Care Options Launches CCO HIV inPractice, a Unique, Free, Comprehensive Online Resource for Healthcare Providers at the Point of Care
3. October 2009 Mayo Clinic Womens HealthSource Highlights Ductal Carcinoma In Situ, New Hearing Aid Options and Self-Acceptance
4. Survey Reveals Parents Are Eager to Learn about Alternative Medicine Options but Information is Lacking
5. On World Menopause Day, October 18, The International Menopause Society and World Health Organization Urge Women to Learn About Their Options for Dealing With Menopause
6. SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options
7. Proposed Medicare Changes Will Increase Costs to Government, Decrease Options for Patients
8. A Staggering 7 Out of 10 Women Facing Breast Cancer Are Never Told of Their Options
9. EdOptions(TM) Offers Schools Affordable Solution to Ensure Continuity of Learning
10. Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
11. New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, ... housing, with more advantaged communities providing richer opportunities. Recognizing the key role of ... school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed by ongoing ... therapy technology, protocols and patient results as have been achieved with Okyanos Cell ... accessible standard of care for patients worldwide. , As the Medical Advisory Chairman at ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
(Date:5/24/2016)... ... ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and ... who do not have access to a toilet, even when they’re on their periods. , ... The (sometimes hilarious) results help shine a light on the awkwardness that women face while ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Een app die artsen over de hele ... behandelen, hun kennis kunnen delen en van elkaar kunnen ... revolutionaire MDLinking App, ontwikkeld door een internationale groep artsen ... en oncologisch chirurg dr. Gijs van Acker . ... dinsdag 24 mei officieel gepresenteerd op het Amsterdam Startup ...
(Date:5/23/2016)... PUNE, India , May 23, 2016 ... is spread across 163 pages, profiles 12 companies and ... 280 tables and figures on the industry and its ... study that is comprehensive in nature, details the current ... of the industry including definitions, classifications, applications and industry ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
Breaking Medicine Technology: